Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Germer
Armin Germer, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20100145911 | Serverless Replication of Databases - The invention relates to a method for carrying out the serverless replication of databases. The inventive method is characterized in that: a copy of the database on at least one peer of the peer-to-peer computer network is modified; a synchronization request due to the modified copy of the database is generated on the at least one peer of the peer-to-peer computer network; the synchronization request is transmitted to all other peers of the peer-to-peer computer network; the synchronization request is received and executed by all the other peers, and; synchronization confirmations are generated after the execution of the synchronization request on each of the other peers and are communicated to all peers or to all peers with the exception of the peer that transmits the synchronization confirmation to the remaining peers. | 06-10-2010 |
Matthias Germer, Langen DE
| Patent application number | Description | Published |
|---|---|---|
| 20090175863 | AGENTS TARGETING CD138 AND USES THEREOF - Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells. | 07-09-2009 |
| 20090232810 | IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF - Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker. | 09-17-2009 |
| 20110059082 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg. | 03-10-2011 |
| 20110059083 | AGENT FOR TREATING DISEASE - The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days. | 03-10-2011 |
| 20110059084 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg. | 03-10-2011 |
Ralph Germer, Austin, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100139682 | Method and apparatus for precise deposition of hair care agents - An apparatus and control method provides for automated, computer control to illuminate hair, sense aspects of that hair, calculate enhancements based on the sensed aspects of the hair, and precisely apply compounds on the hair in spatial conformance with the sensed aspects to create those enhancements. Examples of such compounds are hair coloring agents and hair care agents. | 06-10-2010 |
Soren Germer, Essex County, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090130660 | Single Nucelotide Polymorphism (SNP) - Association of Type 2 diabetes with single nucleotide polymorphisms and haplotypes are disclosed. Also disclosed are diagnostic applications in identifying those who have Type 2 diabetes or are at risk of developing Type 2 diabetes, and discovery of therapeutic agents and methods of treatment. | 05-21-2009 |
Soren Germer, Maplewood, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110262462 | POLYMORPHISM MARKERS FOR PREDICTING RESPONSE TO INTERLEUKIN-6 RECEPTOR-INHIBITING MONOCLONAL ANTIBODY DRUG TREATMENT - The present invention provides single nucleotide polymorphisms (SNPs) associated with clinical responsiveness of rheumatoid arthritis patients to treatment with an interleukin-6 receptor antibody such as tocilizumab, and methods of using such SNPs for predicting clinical response to treatment with the antibody. | 10-27-2011 |